Day: June 21, 2025
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
Data support development of next-generation APJ agonists for obesity and key comorbidities
EMERYVILLE, Calif., June 21, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that it will present new preclinical data supporting apelin receptor (APJ) agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The data will be presented at the American Diabetes Association’s 85th Scientific Sessions, held June 20–23,...
Canadian North Resources Announces Results of 2025 Annual and Special Meeting of Shareholders
Written by Customer Service on . Posted in Public Companies.
TORONTO, June 21, 2025 (GLOBE NEWSWIRE) — Canadian North Resources Inc. (“CNRI” or “the Company,” TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero) is pleased to announce the voting results of its Annual and Special Meeting of Shareholders held on June 19, 2025, in Mississauga, Ontario.
A total of 73,621,572 common shares were voted at the Meeting, representing approximately 64.4% of the Company’s issued and outstanding common shares (114,325,317).
Election of Directors
Shareholders approved the re-election of all five nominees to the Board of Directors. The directors elected to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed are:Nominee
% For
% WithheldLee Q. Shim
99.99%
0.00%
Kaihui Yang
99.99%
0.00%
Aier Wang
99.99%
0.00%
Henderson Tse
99.99%
0.00%
Michael...
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
Written by Customer Service on . Posted in Public Companies.
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting taking place June 21-24, 2025 in New Orleans, Louisiana.Lead author
Abstract Title
Presentation DetailsStephen Graves
[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-α-NET-T101 trial
Abstract Number: 251949Session Type: Poster & OralPoster Session Date: June 21, 2025Oral session: MTA07 Oncology: Clinical Diagnosis & Therapy Meet the Author Session, part 2 Oral Session Date: June 23, 2025Oral Session Time: 12:30 PM...
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
Written by Customer Service on . Posted in Public Companies.
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2
Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data
On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatmentSEATTLE, June 21, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”)...
Jane Silverstone Segal Increases Number of Shares of DAVIDsTEA Inc. Under Her Control
Written by Customer Service on . Posted in Public Companies.
MONTREAL, June 20, 2025 (GLOBE NEWSWIRE) — Jane Silverstone Segal, Chair of the Board of Directors of DAVIDsTEA Inc. (“DAVIDsTEA”) (TSXV: DTEA), announces that on June 20, 2025, she received shares of Rainy Day Investments Ltd. (“RDI”) by way of bequest from her late husband Mr. Herschel Segal, as a result of which Jane Silverstone Segal has voting control of RDI. RDI owns 12,012,538 common shares of DAVIDsTEA, representing 44.51% of DAVIDsTEA’s issued and outstanding common shares, which shares are now controlled by Jane Silverstone Segal.
Immediately prior to the transfer of shares described above, Jane Silverstone Segal held 127,087 common shares of DAVIDsTEA, representing 0.47% of its 26,985,738 issued and outstanding common shares.
Immediately after the transfer of shares described above, Mrs. Segal holds or exercises control,...
Enzon and Viskase Enter into Merger Agreement
Written by Customer Service on . Posted in Mergers And Acquisitions.
Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company
CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) (“Enzon” or the “Company”) and Viskase Companies, Inc. (OTC Pink Limited: VKSC) (“Viskase”) announced that they have entered into a definitive merger agreement (the “Merger Agreement”), pursuant to which Viskase will merge with and into a wholly owned subsidiary of Enzon in an all-stock transaction (the “Merger”). Following the Merger, the combined company is expected to operate under the name “Viskase Holdings, Inc.” and will trade on the “OTCQX” tier of the OTC market of the OTC Markets Group, Inc. The Chief Executive Officer of Viskase Holdings will be Timothy P. Feast, who is currently the Chief Executive Officer...